Consistent with other reported
sigma receptorantagonists, pretreating Swiss Webster mice with BD1008 significantly attenuates the behavioral toxicity of cocaine, and may be potentially useful in the development of antidotes for the treatment of cocaine overdose.[1][2][3][4]
^
abMatsumoto RR, McCracken KA, Pouw B, Miller J, Bowen WD, Williams W, De Costa BR (2001). "N-alkyl substituted analogs of the sigma receptor ligand BD1008 and traditional sigma receptor ligands affect cocaine-induced convulsions and lethality in mice". Eur. J. Pharmacol. 411 (3): 261–73.
doi:
10.1016/s0014-2999(00)00917-1.
^Matsumoto RR, McCracken KA, Friedman MJ, Pouw B, De Costa BR, Bowen WD (May 2001). "Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice". European Journal of Pharmacology. 419 (2–3): 163–74.
doi:
10.1016/S0014-2999(01)00968-2.
PMID11426838.
^Matsumoto RR, Gilmore DL, Pouw B, Bowen WD, Williams W, Kausar A, Coop A (May 2004). "Novel analogs of the sigma receptor ligand BD1008 attenuate cocaine-induced toxicity in mice". European Journal of Pharmacology. 492 (1): 21–6.
doi:
10.1016/j.ejphar.2004.03.037.
PMID15145701.